Grifols 2016 Annual Report On Form 20-F Filed With The SEC On April 4, 2017

BARCELONA, Spain, April 4, 2017 /PRNewswire/ -- Grifols, S.A. (“Grifols”) (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2016 Annual Report on Form 20-F with the United States Securities and Exchange Commission (“SEC”) on April 4, 2017. Grifols’ Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2016.

Form 20-F can be accessed electronically through the Grifols website at http://www.grifols.com/en/web/international/investor-relations/filings-with-other-regulatory-bodies.The Form 20-F is also available on the SEC’s website at http://www.sec.gov.

Grifols will deliver, within a reasonable time after request, a hard copy of the Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at investors@grifols.com to the attention of Grifols’ Investor Relations, Re: 2016 Annual Report on Form 20-F.

About Grifols

Grifols is a global healthcare company with more than a 75-year legacy of improving people’s health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use.

The company is present in more than 100 countries worldwide, with headquarters located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of over 170 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines. As a recognized leader in transfusion medicine, Grifols offers a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks, and transfusion centers.

In 2016, sales exceeded 4,000 million euros with approximately 15,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/grifols-2016-annual-report-on-form-20-f-filed-with-the-sec-on-april-4-2017-300434198.html

SOURCE Grifols

MORE ON THIS TOPIC